title: Targeted skipping of human dystrophin exons in transgenic mouse model systemically for antisense drug development.
abstract: Antisense therapy has recently been demonstrated with great potential for targeted exon skipping and restoration of dystrophin production in cultured muscle cells and in muscles of Duchenne Muscular Dystrophy (DMD) patients. Therapeutic values of exon skipping critically depend on efficacy of the drugs, antisense oligomers (AOs). However, no animal model has been established to test AO targeting human dystrophin exon in vivo systemically. In this study, we applied Vivo-Morpholino to the hDMD mouse, a transgenic model carrying the full-length human dystrophin gene, and achieved for the first time more than 70% efficiency of targeted human dystrophin exon skipping in vivo systemically. We also established a GFP-reporter myoblast culture to screen AOs targeting human dystrophin exon 50. Antisense efficiency for most AOs is consistent between the reporter cells, human myoblasts and in the hDMD mice in vivo. However, variation in efficiency was also clearly observed. A combination of in vitro cell culture and a Vivo-Morpholino based evaluation in vivo systemically in the hDMD mice therefore may represent a prudent approach for selecting AO drug and to meet the regulatory requirement.
authors: McColl-Lockwood Laboratory for Muscular Dystrophy Research, Department of Neurology, Carolinas Medical Center, Charlotte, North Carolina, United States of America. bo.wu@carolinashealthcare.org
authors: Bo
authors: B
authors: Wu
authors: Ehsan
authors: E
authors: Benrashid
authors: Peijuan
authors: P
authors: Lu
authors: Caryn
authors: C
authors: Cloer
authors: Allen
authors: A
authors: Zillmer
authors: Mona
authors: M
authors: Shaban
authors: Qi Long
authors: QL
authors: Lu
references: J Biol Chem. 2008 Feb 29;283(9):5899-907
references: 18083704
references: Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):198-203
references: 15608067
references: Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14814-9
references: 18806224
references: N Engl J Med. 2007 Dec 27;357(26):2677-86
references: 18160687
references: Ann N Y Acad Sci. 2009 Sep;1175:71-9
references: 19796079
references: Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8673-7
references: 8378346
references: Mol Ther. 2004 Aug;10(2):232-40
references: 15294170
references: Lab Invest. 2010 Sep;90(9):1396-402
references: 20458276
references: Cell. 1987 Dec 24;51(6):919-28
references: 3319190
references: N Engl J Med. 2011 Apr 21;364(16):1513-22
references: 21428760
references: Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):42-7
references: 11120883
references: Mol Ther. 2010 Apr;18(4):812-8
references: 20087314
references: Neurology. 1998 Aug;51(2):592-5
references: 9710043
references: Oligonucleotides. 2005 Dec;15(4):284-97
references: 16396622
references: Hum Mol Genet. 1993 Jun;2(6):737-44
references: 8353493
references: Nature. 1990 Jan 11;343(6254):180-2
references: 2404210
references: Nat Med. 2003 Aug;9(8):1009-14
references: 12847521
references: Mol Ther. 2010 Jun;18(6):1210-7
references: 20407428
references: Ann N Y Acad Sci. 2006 Oct;1082:74-6
references: 17145928
references: Nat Med. 2006 Feb;12(2):175-7
references: 16444267
references: RNA Biol. 2010 Jul-Aug;7(4):453-61
references: 20523110
references: Nucleic Acids Res. 2001 Oct 1;29(19):3965-74
references: 11574678
references: Hum Mol Genet. 1998 Jul;7(7):1083-90
references: 9618164
references: Lancet Neurol. 2009 Oct;8(10):918-28
references: 19713152
references: Oligonucleotides. 2010 Apr;20(2):69-77
references: 20377429
references: Gene Ther. 2010 Jan;17(1):132-40
references: 19759562
references: Mol Ther. 2009 May;17(5):864-71
references: 19277018
references: Mol Ther. 2009 Mar;17(3):548-53
references: 18813282
references: Mol Ther. 2007 Jul;15(7):1288-96
references: 17285139
references: Ann Neurol. 2009 Jun;65(6):667-76
references: 19288467
references: Hum Mol Genet. 2003 Apr 15;12(8):907-14
references: 12668614
references: Brain Dev. 2001 Dec;23(8):788-90
references: 11720794